EU and other countries with similar competition laws have regulations against excessive or unfair pricing as part of the abuse of a dominant position (“Excessive Pricing”). Although this regulation is considered difficult to prove, it has been applied in cases such as the pharmaceutical market, and situations under the COVID-19 Pandemic. This paper presents cases of Excessive Pricing from EU, UK, US, China, and South Africa, focusing on the criteria of decision and methods for assessing illegality, and reviews economic arguments. |
CPDP99-J (1,649 KB)
|